EMEA Search Results

Newsroom

Single infusion of CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma

New long-term CARTITUDE-1 data show one-third of patients treated with cilta-cel remain progression-free at five years1 CARTITUDE-4 analysis shows overall survival and progression-free benefits in standard and high-risk subgroups across prior lines of treatment2

Newsroom

European Commission approves TREMFYA® (guselkumab), the first dual-acting IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn’s disease

TREMFYA® (guselkumab) induction therapy administered either intravenously (GALAXI 2 and 3) or subcutaneously (GRAVITI) achieved the co-primary endpoints of clinical remissiona and endoscopic responseb at Week 12 compared to placebo.1,2,3 Guselkumab demonstrated statistically significant and clinically meaningful improvements in clinical remissiona and endoscopic responseb at Week 48 compared to placebo in all three studies.1,2,3 Data from the pooled GALAXI 2 and 3 studies showed that guselkumab demonstrated greater efficacy compared to ustekinumab in endoscopic responseb and endoscopic remissionc both at Week 48, including the biologic naïve and prior biologic failure subgroups.1,2 Guselkumab European Commission approval in Crohn’s disease builds upon recent ulcerative colitis approval,4 marking the fourth indication for this dual-acting IL-23 inhibitor in the European Union.2

Newsroom

Johnson & Johnson submits application to the European Medicines Agency for additional subcutaneous RYBREVANT®▼(amivantamab) dosing regimens to treat patients with EGFR-mutated advanced non-small cell lung cancer

Application supports every-three-week (Q3W) and every-four-week (Q4W) SC amivantamab dosing regimens1 Subcutaneous (SC) amivantamab offers patients greater convenience with reduced administration time from hours to minutes and lower rates of IRRs and associated symptoms compared to the intravenous (IV) formulation2,3

Newsroom

TREMFYA® (guselkumab) shows potential to become the first IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks

Guselkumab subcutaneous (SC) induction demonstrates significant rates of clinical remissiona and endoscopic improvementb at Week 24 compared to placebo in ulcerative colitis1

Newsroom

TREMFYA® (guselkumab) delivers sustained clinical and endoscopic normalisation in ulcerative colitis through two years

Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 921

Newsroom

Johnson & Johnson’s TAR-200 monotherapy demonstrates highest complete response rate reported to date with sustained clinical benefits in patients with certain types of bladder cancer

Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of responders remaining cancer-free at one year after CR1 Results reinforce potential of TAR-200 to transform outcomes for certain types of high-risk non-muscle invasive bladder cancer1

Newsroom

Johnson & Johnson’s TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumours, demonstrating the potential for bladder preservation with 94 percent of patients avoiding radical cystectomy1 Over 95 percent progression-free survival rate at 9-months signals the promise of TAR-200 in this high-risk patient population1

Newsroom

TREMFYA® (guselkumab) receives European Commission approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson’s leadership in inflammatory bowel disease

The firsta approved fully-human, dual-acting interleukin-23 (IL-23) inhibitor in moderately to severely active ulcerative colitis,1,2,3,4,5 guselkumab showed statistically higher rates of endoscopic normalisationb at Week 44 compared with placebo.2,6,7,8,9 Guselkumab is now approved for the treatment of ulcerative colitis in addition to existing indications of plaque psoriasis and psoriatic arthritis in the European Union.2

Newsroom

New long-term progression free survival data projections reinforce subcutaneous DARZALEX® (daratumumab) quadruplet therapy as a foundational standard of care for patients with newly diagnosed multiple myeloma

Median progression free survival projected to be 17 years for transplant eligible patients receiving daratumumab-based regimen1

Newsroom

Johnson & Johnson highlights new data, demonstrating long-term sustained disease control in adults living with generalised myasthenia gravis (gMG)

New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open label extension phase Up to 128 weeks and 180 patient years of follow-up in the open label extension phase demonstrates a safety profile consistent with the Phase 3 Vivacity-MG3 study 45% of the patients receiving steroids at open label extension baseline were able to decrease or discontinue their steroid use Additionally, the nipocalimab plus standard of care (SOC) group demonstrated four times greater odds of improving and maintaining the strength and function of different muscle groups as measured by QMG response versus placebo plus SOC in the 24-week double blind phase of the study

You are now leaving jnj.com/innovativemedicine/emea

You are now leaving jnj.com/innovativemedicine/emea

You are now leaving jnj.com/innovativemedicine/emea

You are now leaving jnj.com/innovativemedicine/emea

You are now leaving jnj.com/innovativemedicine/emea

You are now leaving jnj.com/innovativemedicine/emea

You are now leaving jnj.com/innovativemedicine/emea

You are now leaving jnj.com/innovativemedicine/emea

Search Results

No Results

EMEA Search Results